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Systemic sclerosis (scleroderma) is a disease of unknown cause, the hallmark of which is induration of the skin. Although long regarded as a bland fibrotic process Scleroderma may exist as a localised or a systemic disease process. The latter has been delineated 'progressive systemic sclerosis' in the past, but use of this term has been decried as the disease is not always progressive and because of the emotional burden that this term may place on the patient and the patient's family. 4 In its localised form scleroderma is confined to the skin and adjacent tissues, and it can be classified as linear scleroderma or morphoea (see below). In its systemic form scleroderma may affect a number of visceral organs. Here the classification is somewhat controversial and is based on the extent of cutaneous involvement. Table 1 shows a widely accepted classification, where diffuse (particularly truncal) skin disease is distinguished from limited skin involvement; the latter encompasses and replaces the CREST (calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly, and telangiectasia) variant of scleroderma. Limited cutaneous systemic sclerosis also includes what has been variously designated acrosclerosis, types I and II scleroderma of Barnett, types I and II of the German classification, intermediate cutaneous systemic sclerosis of Giordano, and systemic sclerosis without scleroderma. 4 A recent editorial summarises data which support a conceptual framework of three subtypes of systemic sclerosis: digital, proximal extremity, and truncal,5 but at the present time serological and microvascular data support the simpler classification shown in table 1. 4 By classifying patients into subsets early in the course of the illness, one hopes to identify patients at greater or lesser risk of developing certain visceral complications, as well as provide a more homogeneous group of patients for studies of the pathogenesis, clinical manifestations, and treatment.
Clinical features RAYNAUD' S PHENOMENON
Raynaud's phenomenon refers to episodic digital ischaemia provoked by cold or emotion. Although classically described as triphasicthat is, pallor followed by cyanosis, and then hyperaemia accompanied by numbness and pain, such a three colour response does not occur universally. Pallor seems to be the most reliable sign and hyperaemia the least reliable sign in subjects who lack the classic triphasic response. A recently described questionnaire and colour chart may facilitate the diagnosis of Raynaud's phenomenon. 6 Establishment of the presence or absence of Raynaud's phenomenon is important when evaluating a patient with scleroderma-like skin. The absence of Raynaud's phenomenon should raise the possibility that one might be dealing with a disease other than systemic sclerosis (table 2) as 95% of patients with systemic sclerosis have Raynaud's phenomenon. This distinction is illustrated by the recently described eosinophilia-myalgia syndrome associated with L-tryptophan ingestion, in which sclerodermalike skin lesions commonly accompanied Three phases of dermal involvement have been described. Firstly, there is an oedematous phase, often presenting as stiff and puffy fingers and hands. In this initial phase the condition is often difficult to distinguish from other connective tissue diseases or carpal tunnel syndrome; nailfold capillary microscopy and determination of the presence and type of antinuclear antibody are of greatest diagnostic value in patients in this disease phase. Secondly, an indurative phase, characterised by tightness of the skin, usually follows the oedematous phase. Here, 
GASTROINTESTINAL TRACT DISEASE
Gastrointestinal disease is the most commonly recognised visceral manifestation of systemic sclerosis. Dysphagia and heartburn, the most common symptoms, are due to oesophageal dysmotility and oesophageal reflux. Nearly 85% of patients with systemic sclerosis have been found to have oesophageal reflux using 24 hour pH monitoring of the distal oesophagus.'7 The oesophagus is not affected in localised scleroderma.
Peristaltic abnormalities may delay gastric emptying and may also affect motility of the small and large intestines, at times giving rise to pseudo-obstruction or malabsorption secondary to bacterial overgrowth. Malabsorption may rarely result from pancreatic insufficiency. A recent study concluded that pancreatic exocrine function is often reduced in patients with systemic sclerosis, but rarely to an extent that is clinically important.18 Primary biliary cirrhosis may occur, usually in association with longstanding limited cutaneous systemic sclerosis.
Palliative treatment of gastrointestinal disease is based upon the prevention of gastric reflux and stricture formation by using combinations of antacids, H2 blockers, sucralfate, with elevation of the head of the bed. Severe reflux oesophagitis may respond to treatment with omeprazole. Malabsorption and pseudoobstruction are treated with antibiotics, bowel rest and, at times, parenteral hyperalimentation. The characteristic feature of systemic sclerosis is excessive deposition of collagen and other connective tissue matrix proteins. LeRoy noted that scleroderma dermal fibroblasts synthesise excessive collagen in vitro and that this increased ability to synthesise collagen persists in vitro for a number of passages, before declining towards normal.47 Increased synthesis of glycosaminoglycans and fibronectin has also been shown. Increased concentrations of mRNA of each of these matrix proteins exist in scleroderma dermal fibroblasts. This may result from increased rates of transcription, but increased half lives of the mRNAs may also contribute to increased matrix synthesis in systemic sclerosis.48 49 Recent studies have shown that transforming growth factor ,B may enhance transcription of collagen mRNA through the activation of a promoter region of the collagen gene.50 When injected into experimental animals, transforming growth factor c causes a mononuclear cell inflammatory response and fibrosis.5' Also of potential relevance to systemic sclerosis, transforming growth factor ,B induces the autocrine production of a potent fibroblast mitogen, platelet derived growth factor,52 and it inhibits endothelial cell proliferation in vitro.53 These and other studies support a hypothetical role for transforming growth factor 3 in the induction of the vascular and interstitial lesions of systemic sclerosis.54 VASCULAR 
ASPECTS
The physiological (Raynaud's phenomenon) and pathological (in vivo and postmortem) features of vascular disease in systemic sclerosis have been discussed. Raised plasma concentrations of factor VIII/von Willebrand factor and a platelet product, (3 thromboglobulin, further attest to microvascular and endothelial injury. 55 The mediator of endothelial injury in systemic sclerosis remains controversial. Two recently defined molecules which are capable of causing endothelial injury are tumour necrosis factor a56 and transforming growth factor (.53 Each has the ability to stimulate fibroblast proliferation, as well as induce endothelial injury.
IMMUNOLOGICAL ASPECTS
The common occurrence of antinuclear antibodies and the presence of mononuclear cell infiltrates in the dermis suggest a role for altered immune responsiveness in the pathogenesis of systemic sclerosis. Additional indirect support for this notion is the occurrence of sclerodermalike lesions in patients with chronic graft versus host disease. These and other immunological features have been reviewed recently.' New data implicating the immune response in the pathogenesis of systemic sclerosis are reviewed below.
As noted above, antinuclear antibodies are often found in patients with systemic sclerosis and their first degree relatives, up to 95% of the former and 57% of the latter, when a rapidly dividing, human cell substrate such as HEp-2 is used.43 Two particular antinuclear antibodies deserve mention because of their subset specificity and potential role in pathogenesis. The first is the anticentromere antibody, which recognises three human chromosomal antigens, and which is associated with limited cutaneous systemic sclerosis and patients with Raynaud's phenomenon at risk of developing limited disease.57
The association of anticentromere antibody with certain nailfold capillary abnormalities has been noted'2; both are useful in screening patients with Raynaud's phenomenon for underlying systemic sclerosis.'3 " The second, anti-Scl-70, found in about 30% of patients with diffuse cutaneous systemic sclerosis, is an autoantibody directed against the nuclear enzyme, DNA in the kynurenine pathway, indoleamine-2,3-dioxygenase. Inflammatory mediators, such as endotoxin and interferon y, are known to stimulate the activity of indoleamine-2,3-dioxygenase. It remains to be determined whether endotoxin or interferon y, or both, play a part in the biochemical abnormalities and pathogenesis of the current eosinophilia-myalgia syndrome epidemic. Further studies of tryptophan metabolism in patients with eosinophiliamyalgia syndrome or eosinophilic fasciitis may provide information which is applicable to the pathogenesis of systemic sclerosis.
The eosinophilia and oedematous skin changes, as well as the pneumonitis, associated with eosinophilia-myalgia syndrome generally respond well to corticosteroid treatment. Neuropathy and pulmonary hypertension may persist, and chronic skin changes are now being seen. The natural history of this new epidemic remains to be determined.
Childhood scieroderma
Scleroderma is rare in childhood, and the clinical presentation is even more varied than in adult life.8" Juvenile onset scleroderma may take the form of localised scleroderma (linear or morphoea), including eosinophilic fasciitis,82 or it may occur as systemic sclerosis. In the latter case Raynaud's phenomenon is commonly the presenting symptom. Skin involvement may be classified as localised or diffuse, as with adult onset scleroderma. Visceral organ involvement is similar to the adult form, with oesophageal dysmotility being common, and with cardiac and pulmonary disease primarily responsible for morbidity and mortality. With an HEp-2 cell substrate the prevalence of antinuclear antibodies has been shown to be similar to that in adult scleroderma: in 100% of children with systemic sclerosis and in 67% of children with localised scleroderma.8' Anticentromere antibody has been demonstrated in the rare case of juvenile onset CREST syndrome.83
